Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Orexo AB releases MODIA study findings on illicit opioid use.

Document Cited in Related
Vincent

NORDIC BUSINESS REPORT-October 11, 2023-Orexo AB releases MODIA study findings on illicit opioid use

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Wednesday reported top-line results of a study evaluating the efficacy of MODIA in conjunction with sublingual buprenorphine/naloxone for treating opioid use disorder (OUD) and reducing the use of illicit opioids.

MODIA is a web-based software program intended to help OUD patients develop behavioural coping skills and provide educational information, reminders and motivational guidance. MODIA is intended for use by patients engaged in a clinician directed Medication-Assisted Treatment (MAT) plan for OUD.

The six-month randomized controlled trial enrolled 437 participants across 36 US sites and demonstrated high treatment response rates in both treatment arms, with no statistically significant difference in treatment response in the full population. No adverse events associated with MODIA usage were reported.

...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT